Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1476
Knight Transportation
KNX
$11.9B
| $13.5M | ﹤0.01% |
257,407
-210,353
| -45% | -$9.86M |
|
1477
Vipshop
VIPS
$6.8B
| $13.5M | ﹤0.01% |
760,593
+283,733
| +60% | +$5.46M |
|
1478
OGE Energy
OGE
$9.71B
| $13.4M | ﹤0.01% |
314,951
+134,990
| +75% | +$6.02M |
|
1479
United Bankshares
UBSI
$6.68B
| $13.4M | ﹤0.01% |
350,077
+10,510
| +3% | +$391K |
|
1480
CALL
Dynatrace
DT
$14.7B
| $13.4M | ﹤0.01% |
310,000
+270,000
| +675% | +$12.6M |
|
1481
FIVE9
FIVN
$2.53B
| $13.4M | ﹤0.01% |
666,930
-117,777
| -15% | -$2.5M |
|
1482
CareTrust REIT
CTRE
$9.18B
| $13.3M | ﹤0.01% |
368,508
+45,700
| +14% | +$1.64M |
|
1483
CALL
Ford
F
$55.4B
| $13.3M | ﹤0.01% |
1,015,000
-385,000
| -28% | -$4.96M |
|
1484
TG Therapeutics
TGTX
$7.34B
| $13.3M | ﹤0.01% |
446,720
-11,505
| -3% | -$376K |
|
1485
Golar LNG
GLNG
$5.21B
| $13.3M | ﹤0.01% |
356,660
+189,800
| +114% | +$7.26M |
|
1486
BHP
BHP
$222B
| $13.3M | ﹤0.01% |
219,779
-58,822
| -21% | -$3.34M |
|
1487
Portland General Electric
POR
$5.92B
| $13.3M | ﹤0.01% |
276,424
-490,111
| -64% | -$23.1M |
|
1488
Alignment Healthcare
ALHC
$2.79B
| $13.2M | ﹤0.01% |
669,533
-678,201
| -50% | -$12.2M |
|
1489
WD-40
WDFC
$3.09B
| $13.2M | ﹤0.01% |
67,066
+4,087
| +6% | +$806K |
|
1490
CALL
American Eagle Outfitters
AEO
$2.73B
| $13.2M | ﹤0.01% |
500,000
| – | – |
|
|
1491
PUT
American Eagle Outfitters
AEO
$2.73B
| $13.2M | ﹤0.01% |
500,000
-500,000
| -50% | -$9.88M |
|
1492
Manhattan Associates
MANH
$11.7B
| $13.2M | ﹤0.01% |
76,053
-8,125
| -10% | -$1.49M |
|
1493
Silicon Laboratories
SLAB
$7.28B
| $13.1M | ﹤0.01% |
100,362
+8,431
| +9% | +$1.11M |
|
1494
Commault Systems
CVLT
$6.26B
| $13.1M | ﹤0.01% |
104,634
+100
| +0.1% | +$14.1K |
|
1495
CRISPR Therapeutics
CRSP
$5.22B
| $13.1M | ﹤0.01% |
249,988
-99,863
| -29% | -$5.98M |
|
1496
Bright Horizons
BFAM
$3.85B
| $13.1M | ﹤0.01% |
129,055
+56,872
| +79% | +$5.74M |
|
1497
Granite Construction
GVA
$5.41B
| $13M | ﹤0.01% |
113,037
+13,685
| +14% | +$1.47M |
|
1498
Lucid Motors
LCID
$2.54B
| $13M | ﹤0.01% |
1,230,911
+237,913
| +24% | +$3.8M |
|
1499
Saia
SAIA
$10.1B
| $13M | ﹤0.01% |
39,769
+1,277
| +3% | +$386K |
|
1500
Moog Inc Class A
MOG.A
$13.5B
| $13M | ﹤0.01% |
53,220
+978
| +2% | +$215K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.